Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service lumbar fusion cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (239 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 85 | 3,461 | 46% |
| 2020 | 67 | 2,907 | 48% |
| 2021 | 84 |
Posterolateral, interbody, and anterior lumbar fusion with instrumentation. Professional codes (what the surgeon bills): CPT 22612, 22630, 22633, 22558; the hospital bills MS-DRG 453, 454, 455, 459, 460, 402, 426, 427, 428, 447, 448, 450, 451, 523, 524, 525.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 25% of the cases CMS names in New York; 62 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 89 | 3,644−1.8%/yr | −1.8%/yr | 2.6 | 3% | 3,820 in 2030+0.8%/yr |
| Massachusetts | 61 | 2,186 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 113 | 4,671−4.3%/yr | −4.3%/yr | 2.50.9× | 3% | 4,720 in 2030+0.2%/yr |
| Cervical fusion & disc arthroplasty |
Lumbar fusion in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
| 2024 |
| 3,407 |
| 57% |
| 2025 est. | ≈ 3,580 | – |
| 2026 est. | ≈ 3,690 | – |
| 3,082 |
| 51% |
| 2022 | 88 | 3,107 | 53% |
| 2023 | 90 | 3,317 | 55% |
| 2024 | 96 | 3,407 | 57% |
| 2025 from claims | – | 3,582 3,287–3,790 | 58% |
| 2026 forecast | – | 3,685 3,242–4,252 | 58% |
| 2027 forecast | – | 3,775 3,227–4,499 | 59% |
| 2028 forecast | – | 3,867 3,226–4,735 | 59% |
| 2029 forecast | – | 3,960 3,234–4,966 | 60% |
| 2030 forecast | – | 4,055 3,248–5,196 | 60% |
In 2025, 90% inpatient hospital, 10% hospital outpatient, 1% surgery center.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +0.3%/yr |
| 2.3 |
| 0% |
| 2,550 in 2030+2.6%/yr |
| New Jersey | 40 | 1,764+6.8%/yr | +6.8%/yr | 1.6 | 11% | 2,120 in 2030+3.1%/yr |
| Connecticut | 25 | 965+0.5%/yr | +0.5%/yr | 2.8 | 0% | 1,000 in 2030+0.5%/yr |
| New Hampshire | 6 | 324−6.1%/yr | −6.1%/yr | 1.4 | 0% | 500 in 2030+7.7%/yr |
| Rhode Island | 8 | 294−2.1%/yr | −2.1%/yr | 3.1 | 0% | 460 in 2030+7.8%/yr |
| 35 |
| 1,875−1.6%/yr |
| −1.6%/yr |
| 1.00.9× |
| 2% |
| 1,980 in 2030+0.9%/yr |
| Kyphoplasty & vertebroplasty | 12 | 1,432−3.1%/yr | −3.1%/yr | 0.80.9× | 29% | 1,740 in 2030+3.3%/yr |
| SI joint fusion | 0 | 175+8.8%/yr | +8.8%/yr | 0.10.7× | 0% | 450 in 2030+17%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 21,243 spine fusion (all regions) stays at 83 hospitals in 2024, against the Medicare-only figures above. The most commercial of the busy ones is COHEN'S CHILDREN MEDICAL CENTER W/ LIJ (65% commercial): where commercial rates leave the most room for a premium product.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| HOSPITAL FOR SPECIAL SURGERY NEW YORK | 1,920 | 38% | 55% |
| NYU LANGONE HOSPITALS NEW YORK | 1,788 | 45% | 30% |
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 1,520 | 33% | 37% |
| KALEIDA HEALTH BUFFALO | 1,049 | 39% | 25% |
| MOUNT SINAI HOSPITAL NEW YORK | 951 | 50% | 38% |
| MERCY HOSPITAL OF BUFFALO BUFFALO | 702 | 48% | 16% |
| LENOX HILL HOSPITAL NEW YORK | 618 | 49% | 38% |
| CROUSE HOSPITAL SYRACUSE | 594 | 51% | 25% |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (Spine fusion (all regions): lumbar, thoracic and cervical together: the file does not split them.). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.
Medtronic leads with 30% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 29 companies reported engagement with New York’s surgeons worth $1.4M in consulting, speaking, meals and travel tied to these products, about $15K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 87 clearances and approvals in the category, 12 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.